Colgate-Palmolive (CL) Stock Forecast & Price Target

Colgate-Palmolive is supported by a resilient international franchise that has compounded at mid- to high-single-digit organic growth, with Europe gaining about 300 bps of toothpaste share since 2016 through a proven two-brand strategy and emerging markets providing broad-based momentum. Its Hill’s pet nutrition business adds another durable growth engine, while announced cost savings of up to $500–575MM from the Global Growth and Efficiency Program should support margin expansion and earnings resilience. The main weakness is North America, where negative organic sales in the majority of the past two years, innovation gaps in whitening and premium therapeutics, and competition from Haleon have capped upside, but the company’s European playbook and recent improvement in Total suggest a credible path to stabilization.

Colgate-Palmolive is facing a fundamentally weaker setup because management’s self-inflicted pricing and promotional mistakes in 2023 accelerated share losses in oral care and hand dish, while under-investment in North America marketing left P&G and Haleon room to gain. North America has been down about 2% over the last 8 quarters and Colgate has underperformed HPC peers by roughly 250 bps, with its toothpaste portfolio priced at a more than 50% discount to Haleon and 28% to PG, underscoring a lack of premium mix power. Heavy exposure to international markets, including nearly half from emerging regions, also leaves the company vulnerable to currency swings, input-cost volatility, and, even with some relief expected in 2027, gross margin pressure still likely in 2026.